Seeking Alpha
 

United Therapeutics Corporation (UTHR)

- NASDAQ
  • Oct. 31, 2012, 5:30 PM
    Notable earnings before Thursday’s open: ABC, ABX, ADP, ALKS, APA, AVP, BCE, BYD, CI, CNSL, CTRX, CVC, DLPH, DX, EL, EPD, ESV, EXC, FIRE, GAS, GNC, GTLS, HEP, HSH, INCY, ITRI, IVZ, K, LLL, MPC, NGLS, NIHD, OCN, PEG, PFE, PXP, RDN, RGLD, SE, SIRI, SNE, SPR, TDC, TE, TEVA, UPL, UTHR, VNR, WNR, WPI, XOM, XYL
    | Comment!
  • Oct. 24, 2012, 12:45 PM
    Midday top 10 gainers: SEH +61%. KIPS +25%. CHC +21%. FB +21%. LL +15%. PLCM +14%. ASPS +11%. DHX +12%. MNST +13%. CYCC +12%. Top 10 Losers: TPX -22%. IRBT -19%. CPWR -16%. UIS -15%. NFLX -14%. DSCO -14%. UTHR -13%. BWLD -12%. NSM -12%. NFX -12%.
    | Comment!
  • Oct. 24, 2012, 9:10 AM
    Premarket gainers: SEH +62%. FB +26%. RFMD +14%. LL +13%. RENN +11%. POL +10%. DOW +6%. ZNGA +5%. GRPN +5%. MM +6%.
    Losers: TPX -21%. NFLX -18%. DSCO -14%. UTHR -12%. INVN -8%. KMT -7%. XOMA -7%.
    | Comment!
  • Oct. 24, 2012, 8:25 AM
    United Therapeutics (UTHR) dives 11.8% after yesterday saying that the FDA has turned down the company's new drug application for treprostinil, an oral treatment for high blood pressure. The agency is uncertain whether another study would help change its mind, but said that if UTHR does decide on a further trial, it should consider a fixed dose design and more frequent dosing. (PR)
    | 1 Comment
  • Oct. 23, 2012, 5:40 PM
    After-hours top gainers, as of 5:15 p.m.: RFMD +12%; TWIN +9.2%; FB +8.2%; IDIX +6.5%; PNRA +6.4%.
    After-hours top losers: INVN -19.1%; TPX -18.4%; IRBT -15.2%; BWLD -10.2%; UTHR -9.9%.
    | 1 Comment
  • Jul. 26, 2012, 10:40 AM
    United Therapeutics (UTHR): Q2 EPS of $1.34 beats by $0.11. Revenue of $225.6M (+22.7% Y/Y) beats by $12.27M. (PR)
    | Comment!
  • Apr. 26, 2012, 11:59 AM
    United Therapeutics (UTHR): Q1 EPS of $1.32 beats by $0.32. Revenue of $204M (+25.7% Y/Y) in-line. (PR)
    | Comment!
  • Apr. 12, 2012, 11:33 AM
    United Therapeutics (UTHR -2.6%) shares are downgraded to Market Perform from Outperform with a new price target of $48 from $65 by Leerink Swann, which cites generic risk to its treatment of pulmonary arterial hypertension. A recent survey by the firm says "most physicians believe that a minority of their patients are candidates for oral Remodulin."
    | Comment!
  • Mar. 20, 2012, 3:49 PM
    Argus lines up United Therapeutics (UTHR -1.4%) as an undervalued name in the healthcare sector, as it maintains a Buy rating on the biotech concern. Analysts with the firm expect Argus to hit its 2012 sales target, as they raise their price target on shares by $8 to $60.
    | Comment!
  • Mar. 15, 2012, 8:26 AM
    United Therapeutics (UTHR) files a patent infringement lawsuit against Novartis' (NVS) Sandoz unit over patents related to a pulmonary hypertension drug. Sandoz aims to sell a generic version of United's Remdoulin drug. NVS +0.2% premarket, UTHR inactive.
    | Comment!
  • Feb. 14, 2012, 7:37 AM
    United Therapeutics (UTHR): Q4 EPS of $0.77 misses by $0.08. Revenue of $195.2M (+19.2% Y/Y) misses by $9M. (PR)
    | Comment!
  • Feb. 14, 2012, 12:05 AM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
  • Feb. 13, 2012, 5:30 PM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
  • Jan. 6, 2012, 10:39 AM
    Sabrient Systems reveals its “Baker’s Dozen” list of 13 stocks to buy and hold through the calendar year: STX, WNR, OCN, WPI, UTHR, CLD, GSM, DAN, AGCO, DXPE, KRO, URI, ASCA. Sabrient's lists have easily outperformed the S&P in each of the past three years.
    | Comment!
  • Dec. 27, 2011, 11:17 AM
    United Therapeutics (UTHR -0.7%) says its wholly owned subsidiary, United Therapeutics Europe, has received approval from French regulators for its New Drug Application for Intravenous Remodulin for the treatment of pulmonary arterial hypertension.
    | Comment!
  • Oct. 27, 2011, 8:44 AM
    United Therapeutics (UTHR): Q3 EPS of $1.65 beats by $0.92. Revenue of $202M (+19% Y/Y) beats by $7M. (PR)
    | Comment!
Visit Seeking Alpha's
UTHR vs. ETF Alternatives
Company Description
United Therapeutics Corp is a biotechnology company. The Company is engaged in thedevelopment and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.